| 生物活性 |
Liposomal Coenzyme Q10 is an orally effective delivery system that encapsulates liposoluble coenzyme Q10 (CoQ10) (MS-F73035) via liposomal nanocarriers, and it can alleviate hepatic oxidative stress, mitigate hepatic inflammatory responses, reduce hepatocyte apoptosis (apoptosis), and improve liver fibrosis, while also activating the ferroptosis suppressor protein 1 (FSP1)/coenzyme Q10 system, reducing the accumulation of malondialdehyde and ROS, and inhibiting neuronal ferroptosis (ferroptosis), and it can be used for research related to Propanoic acid (Propanoic acid) (MS-K59357)-induced liver injury and subarachnoid hemorrhage. |
体内研究 (In Vivo) |
Liposomal Coenzyme Q10 (10 mg/kg/天;口服;每日给药;连续 5 天) 可通过减轻氧化应激、炎症、细胞凋亡和纤维化来缓解丙酸诱导的肝损伤,并改善肝脏组织学结构。 Liposomal Coenzyme Q10 (100 mg/kg;静脉注射;每日 1 次;连续 3 天) 可激活 FSP1/CoQ10 系统、抑制神经元铁死亡,并相较于溶媒组和非靶向脂质体组改善蛛网膜下腔出血 (SAH) 模型小鼠的神经功能,但其效果弱于神经元靶向的 CoQ10-Tet1-Lipos。
| Animal Model: |
Albino rats (adult male, 150-170 g, propionic acid-induced liver injury) |
| Dosage: |
10 mg/kg/day; 100 mg/kg/day (acetyl-L-carnitine, combination group) |
| Administration: |
p.o.; daily; 5 days (administered one hour after propionic acid) |
| Result: |
Marked reduction in serum AST, ALT, and LDH activity levels compared to the propionic acid-only group. Significant reduction in hepatic malondialdehyde (MDA) levels, and significant restoration of hepatic reduced glutathione (GSH) levels and superoxide dismutase (SOD) enzyme activity compared to the propionic acid-only group. Significant downregulation of hepatic proinflammatory cytokines IL-6 and TNF-α levels compared to the propionic acid-only group. Significant reduction in hepatic caspase-3 levels, and significant downregulation of hepatic cytokeratin-18 (CK18) mRNA expression compared to the propionic acid-only group. Significant downregulation of hepatic transforming growth factor-beta1 (TGF-β1) and SMAD3 protein expression compared to the propionic acid-only group. Significant downregulation of hepatic high-mobility group box-1 (HMGB1) mRNA expression compared to the propionic acid-only group. Showed intact lobular hepatic architecture, with hepatocytes arranged in thin plates and only mild hydropic degeneration, compared to the propionic acid-only group which exhibited intracytoplasmic vacuoles, congested/dilated sinusoids, and necrotic areas; combination group showed almost normal hepatic structure and architecture. |
| Animal Model: |
C57BL/6 (male, 6-8 weeks old, 20-25 g, intracranial vessel puncture via external carotid artery insertion of a monofilament) |
| Dosage: |
100 mg/kg |
| Administration: |
i.v.; daily; 3 days |
| Result: |
Increased FSP1 levels at the lesion site relative to SAH-only, Lipos, and Tet1-Lipos groups, though to a lesser extent than the CoQ10-Tet1-Lipos group. Reduced lesion-site iron content relative to SAH-only, Lipos, and Tet1-Lipos groups, though to a lesser extent than the CoQ10-Tet1-Lipos group. Reduced lesion-site MDA concentration relative to SAH-only, Lipos, and Tet1-Lipos groups, though to a lesser extent than the CoQ10-Tet1-Lipos group. Reduced oxidative stress (measured via 8-OHdG fluorescence intensity) relative to SAH-only, Lipos, and Tet1-Lipos groups, though to a lesser extent than the CoQ10-Tet1-Lipos group. Increased the number of morphologically normal neurons at the lesion site relative to SAH-only, Lipos, and Tet1-Lipos groups, though to a lesser extent than the CoQ10-Tet1-Lipos group. Inhibited neuronal ferroptosis (preserved mitochondrial morphology via TEM) relative to SAH-only, Lipos, and Tet1-Lipos groups, though to a lesser extent than the CoQ10-Tet1-Lipos group. Produced shorter latency to find the platform and longer time spent in the correct quadrant in the Morris water maze test relative to SAH-only, Lipos, and Tet1-Lipos groups, though to a lesser extent than the CoQ10-Tet1-Lipos groups, indicating improved spatial memory. Achieved a higher modified Garcia score relative to SAH-only, Lipos, and Tet1-Lipos groups, though to a lesser extent than the CoQ10-Tet1-Lipos group, indicating improved sensory and motor function. Resulted in shorter time to reach the 20 cm mark in the chimney behavioral test relative to SAH-only, Lipos, and Tet1-Lipos groups, though to a lesser extent than the CoQ10-Tet1-Lipos group, indicating improved motor function. Had a mortality rate of 15.63% (10/64) in behavioral test groups and 17.24% (5/29) in tissue collection groups, comparable to other SAH treatment groups. |
|